Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 6, Pages 1484-1494
Publisher
Wiley
Online
2013-09-07
DOI
10.1002/ijc.28475
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development and Evaluation of a Novel Microemulsion Formulation of Elacridar to Improve its Bioavailability
- (2013) Ramola Sane et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
- (2013) Denis Maillet et al. Journal of Thoracic Oncology
- Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement–Positive Non–Small-Cell Lung Cancer
- (2013) Hiroyasu Kaneda et al. Journal of Thoracic Oncology
- ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
- (2012) Wen-jing Zhou et al. BRITISH JOURNAL OF PHARMACOLOGY
- Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
- (2012) Robert C. Doebele et al. CANCER
- Liquid chromatography–tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma
- (2012) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2012) Leena Gandhi et al. Journal of Thoracic Oncology
- Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: A case report
- (2012) Alexander T. Falk et al. LUNG CANCER
- Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
- (2012) Selvi Durmus et al. MOLECULAR PHARMACEUTICS
- Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration
- (2011) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor
- (2011) Andrew S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Global Patterns of Cancer Incidence and Mortality Rates and Trends
- (2010) A. Jemal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- (2008) U. McDermott et al. CANCER RESEARCH
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started